07:00 , Sep 27, 2010 |  BC Week In Review  |  Company News

Asthmatx, Boston Scientific deal

Boston Scientific will acquire fellow medical device company Asthmatx for $193.5 million up front in cash, plus up to $250 million in revenue-based milestones. Asthmatx markets its Alair bronchial thermoplasty system, which FDA approved in...
00:47 , Sep 21, 2010 |  BC Extra  |  Company News

M&A: Boston Scientific buying Asthmatx

Boston Scientific Corp. (NYSE:BSX) will acquire fellow medical device company Asthmatx Inc. (Sunnyvale, Calif.) for $193.5 million up front in cash, plus up to $250 million in revenue-based milestones. Asthmatx markets its Alair bronchial thermoplasty...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

Alair System regulatory update

FDA approved a PMA from Asthmatx for the Alair bronchial thermoplasty system to treat adults whose severe and persistent asthma is not well-controlled with an inhaled corticosteroid and a long-acting adrenergic receptor beta 2 (ADRB2)...
00:02 , Apr 28, 2010 |  BC Extra  |  Company News

FDA approves Alair asthma device

FDA approved the Alair bronchial thermoplasty system from Asthmatx Inc. (Sunnyvale, Calif.) to treat adults whose severe and persistent asthma is not well-controlled with an inhaled corticosteroid and a long-acting adrenergic receptor beta 2 (ADRB2)...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

Alair System regulatory update

FDA's Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee voted 6 to 1 to recommend approval of a PMA from Asthmatx for Alair System to treat severe persistent asthma in adults....
07:00 , Aug 17, 2009 |  BioCentury  |  Product Development

Heating up the airways

Asthmatx Inc. believes its Alair bronchial thermoplasty system will significantly improve quality of life for patients with severe asthma who are not adequately served by drugs. If successful, the treatment would be added on to...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Alair System: Phase III data

Data from the double-blind, international Phase III AIR2 trial in 297 patients showed that Alair significantly improved the average AQLQ scores at 6-, 9- and 12- months compared with the sham control (80% vs. 64%)....
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

Anthera management update

Anthera Pharmaceuticals Inc. , San Mateo, Calif.   Business: Pulmonary, Inflammation   Hired: Christopher Lowe as CFO and VP of administration, formerly CFO and VP of finance and administration at Asthmatx Inc.  ...